Abzena has announced upgrades of its chemistry GMP suites.
The Bristol PA site manufacturing facility upgrades will allow Abzena’s ADC client projects to progress from discovery to commercial without technology transfer.
The enhancements include two GMP suites, one for small molecules, including high potency up to 100L scale, and one for conjugation, as well as other GMP facility upgrades.
Jonathan Goldman, CEO of Abzena said: “Customer demand for our high quality, integrated services has increased 93% since 2019. This has driven our decision to invest in our capacity for commercial GMP capacity for ADCs. We are delighted to augment our market leading discovery, design and development capability and add to our outstanding scientific team.”
Goldman continued: “Abzena is committed to being the best-in-class provider of fully integrated drug discovery and development services of biologics and ADC, supported by unrivalled experience. We look forward to supporting our partners and the patients they serve.”